Ariad’s Iclusig Cleared For European Approval By CHMP
This article was originally published in The Pink Sheet Daily
Europe's top scientific advisory panel, CHMP, granted positive opinions for Ariad's new leukemia therapy Iclusig, Gilead's four-drug HIV therapy, Stribild and Baxter's subcutaneous IgG formulation, HyQvia, at its March 2013 meeting,
You may also be interested in...
CBER’s Blood Products Advisory Committee votes in favor of communication strategies to mitigate the risks of Baxter’s primary immune deficiency treatment but not to monitor for possible adverse events associated with long-term exposure.
Agency officials say long-term immunogenicity issues could manifest among patients taking proposed primary immunodeficiency disorder treatment, but advisory committee concludes risk can be managed.
The EMA’s CHMP has given the nod to Sanofi’s Aubagio and Biogen Idec’s Tecfidera for multiple sclerosis, setting the scene for a European three-way battle with Novartis’ Gilenya in the coming months.